Nodality to Collaborate with Pfizer on Compounds for Autoimmune Disease

Nodality and Pfizer have announced a new collaborative effort to investigate potential compounds for autoimmune disease.

Nodality Inc, a personalised medicine biotechnology company based in south San Francisco, has entered into a strategic collaboration with Pfizer.

Under the multi-year agreement, Nodality's proprietary single cell network profiling (SCNP) technology will be used as a tool to develop potential Pfizer compounds for autoimmune diseases.

Initially, efforts will centre around potential compounds for lupus, including characterising mechanisms of action, disease analysis and drug profiling.

Pfizer also has the option to ally with Nodality for the development of companion diagnostics.

Michael Goldberg, executive chairman and interim chief executive officer of Nodality, said: "We are excited to be working with Pfizer's world class autoimmune R&D groups to enhance their drug development activities.

"This collaboration, which is Nodality's second major strategic pharma partnership this ye